Spots Global Cancer Trial Database for PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Official Title: PS-341 (Bortezomib, Velcade®), Adriamycin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide With Dexamethasone (Thal/Dex) for Relapsed or Refractory Multiple Myeloma
Study ID: NCT00319865
Conditions
Study Description
Brief Summary: Prospective multicenter phase 2 study using PAD and Thal/Dex combination sequentially.
Detailed Description: Although the overall survival was improved with the introduction of high dose therapy with autologous hematopoetic stem cell transplantation,it remains as a incurable disease. Most patients ultimately relapse. Recenlty, targeted therapy using novel agents, such as bortezomib and thalidomide, shows the possibility of improved in this situation. Among them, PAD (Velcade, Adriamycin,Dexamethasone) showed highest response rate. PAD does not show any cross resiatance with another effective combination, thalidomide plus dexamethasone. We desined prospective multicenter phase 2 study using these combination sequentially.
Keywords
Eligibility
Minimum Age: 0 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Gachon University Gil Hospital, Inchon, , Korea, Republic of
Contact Details
Name: Jae Hoon Lee, M.D.
Affiliation: Korean Multiple Myeloma Working Party
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
